News

Evolocumab reduces LDL-C levels by 44% in children with familial hypercholesterolaemia

Selon une nouvelle étude, l’Evolocumab (Repatha) a amélioré de manière significative les taux de cholestérol à lipoprotéines de basse densité (LDL-C) chez les enfants souffrant d’hypercholestérolémie familiale.

Les résultats de l’étude de phase 3, présentés lors d’une séance de clôture du Congrès 2020 de la Société européenne de cardiologie (ESC) ce week-end, incitent les cliniciens à mieux comprendre les avantages de la classe des inhibiteurs de PCSK9 chez les enfants souffrant de la maladie monogénique la plus répandue dans le monde.

 

Read the article on HCP Live

Read more

  • News

    MEDTEQ+ Health Orbit Program: 6 Canadian companies to support astronauts and remote communities with health technology innovations

    Deep Breathe Inc, Applications MD, Momentum Health, Nura Medical, ECOGENE-21 and Myomar Molecular are the Canadian companies selected as part of the MEDTEQ+-powered Health Orbit program, which aims to support Canadian companies in the development of technologies to meet telemedicine and autonomous healthcare needs on Earth and in space.
    Read more
  • Works

    A drone successfully delivers medicines over 150 km to help isolated patients

    A drone belonging to Delair, a company based in Toulouse (Haute-Garonne), has made a long-distance delivery of medicines. The 150 km test flight will be used to validate its future use in Quebec to deliver medicines to isolated patients.
    Read more
  • News

    ECOGENE-21 tests drone delivery of medicines and samples in Alma

    People who suffer from rare diseases, or who have very specific medical monitoring needs, could see their treatment improved through the use of drones. To help make this a reality one day, the Saguenay-based ECOGENE-21 group recently took part in tests using small remote-controlled aircraft to deliver medicines or medical samples to remote areas.
    Read more